Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

Rhea-AI Summary

Solventum (NYSE: SOLV) announced international consensus recommendations on the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings, published Dec 17, 2025 in the International Wound Journal. The panel issued 12 consensus statements guiding dressing selection, risk-based indications (recommended for patients with ≥2 risk factors), and technical application tips.

A peer-reviewed meta-analysis of 84 studies cited reduced surgical site complications, dehiscence, skin necrosis and readmissions versus standard dressings. Solventum highlighted Prevena™ as the only ciNPT system using ROCF dressings and expanded area dressings for complex incisions.

Positive

• Meta-analysis of 84 studies showing reduced SSC, dehiscence, necrosis and readmissions
• 12 consensus statements providing standardized guidance for ciNPT with ROCF
• Clear risk rule: recommended use for patients with ≥2 risk factors
• Product differentiation: Prevena is the only ciNPT using ROCF dressings

Negative

• None.

Key Figures

Meta-analysis size 84 studies Peer-reviewed meta-analysis across various surgical specialties for ciNPT

Consensus statements 12 statements International panel guidance on ciNPT with ROCF

Risk factor threshold ≥ 2 risk factors Indication threshold for ciNPT dressings with ROCF

Top priorities Top three Patient safety cited as one of top three global priorities

Current share price $80.59 Price prior to publication of consensus recommendations

52-week range $60.70–$88.20 52-week low and high before this article

Market capitalization $14,203,620,443 Equity value prior to the new guidance article

Registered resale shares 34,369,190 shares Shares registered for resale by 3M under Form S-3

Market Reality Check

$80.68 Last Close

Volume Volume 1,055,818 is slightly below the 20-day average of 1,140,205 (relative volume 0.93). normal

Technical Shares at $80.59 are trading above the 200-day MA of $73.45 and 8.63% below the 52-week high of $88.20.

Peers on Argus

SOLV was down 1.59% with volume slightly below average. Key peers BAX, HOLX, COO, WST, and RMD also showed negative moves (e.g., BAX -2.51%, WST -1.77%), indicating a generally weak tape across medical instruments but without enough coordinated momentum to flag a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 25	Conference participation	Neutral	-0.6%	Announcement of participation in Piper Sandler Healthcare Conference fireside chat.
Nov 20	Strategic acquisition	Positive	+2.9%	Cash acquisition of Acera Surgical to expand MedSurg into synthetic tissue matrices.
Nov 20	Share repurchase	Positive	+2.9%	Board authorization of a <b>$1B</b> share repurchase program starting in 2026.
Nov 06	Earnings update	Positive	-2.1%	Q3 2025 results with raised guidance and new cost‑savings program.
Nov 03	Conference participation	Neutral	+0.7%	Participation announcement for the 2025 Stifel Healthcare Conference.

Pattern Detected

Stock reactions have generally aligned with the directional tone of news, except for a negative move on otherwise constructive Q3 2025 results and guidance.

Recent Company History

Over the last few months, Solventum has combined portfolio reshaping and capital returns with routine investor outreach. On Nov 6, 2025, Q3 results showed $2.096B in net sales and raised full‑year adjusted EPS guidance to $5.98–$6.08, yet shares fell 2.08%. On Nov 20, 2025, the company announced a $725M cash acquisition of Acera Surgical and a $1B share repurchase authorization, with shares up 2.85%. Conference participation headlines in early November saw modest, mixed moves, consistent with neutral catalysts.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-08-13

An effective Form S-3ASR filed on Aug 13, 2025 registers up to 34,369,190 Solventum shares held by 3M Company for resale. All proceeds from any such sales go to 3M, and Solventum will not receive proceeds. The registration remains effective under a Registration Rights Agreement through Aug 13, 2027 or until all registered shares are sold.

Market Pulse Summary

This announcement details international consensus recommendations on the advanced use of ciNPT with ROCF dressings, reinforcing its role in managing high‑risk surgical incisions. It highlights evidence from a meta‑analysis of 84 studies and 12 consensus statements guiding risk‑based indications, dressing selection and application techniques. In context of Solventum’s broader strategy, including recent portfolio actions and capital programs, investors may track adoption of these recommendations, any shifts in surgical procedure coverage, and future clinical data supporting Prevena‑branded solutions.

Key Terms

closed incision negative pressure therapy medical

"new recommendations on the clinical use of closed incision negative pressure therapy (ciNPT)"

A therapy that gently applies suction over a stitched or closed surgical cut to remove fluid, reduce swelling and infection risk, and help the skin heal more neatly—think of a small vacuum dressing protecting a fresh repair. Investors watch this technology because it can shorten hospital stays, cut complication-related costs and drive steady device and consumable sales when adopted by surgeons and reimbursed by insurers, affecting growth and margins.

reticulated open cell foam medical

"advanced use of ... negative pressure therapy with reticulated open cell foam (ROCF) dressings"

Reticulated open cell foam is a sponge‑like material whose cell walls have been removed to leave a network of interconnected strands and large pores, allowing air and liquids to pass through easily. Investors care because this material is used in filters, cushioning, acoustic insulation and medical devices; its performance, cost, supply availability and regulatory or sustainability shifts can affect product quality, manufacturing margins and demand across multiple industries.

seroma medical

"incisions at high risk of seroma formation, revision surgeries, traumatic wounds"

A seroma is a pocket of clear fluid that can collect under the skin after surgery, injury, or a medical procedure, similar to a small blister filled with water rather than blood. For investors, seromas matter because they can indicate device or procedure complications, influence clinical trial results, increase treatment costs, trigger regulatory scrutiny, or lead to product liability — all of which can affect a medical company’s revenues and reputation.

lymphedema medical

"sites prone to edema or lymphedema. Linear dressings remain effective"

Lymphedema is a chronic swelling that happens when the body’s fluid-draining network can’t move fluid away from tissues, causing persistent puffiness, heaviness and sometimes skin changes. Investors pay attention because it represents a steady demand for diagnostics, drugs, devices and long-term care—think of it like a clogged drain that creates ongoing repair and maintenance needs, so new treatments or devices can shift patient outcomes and company revenue for years.

adjuvant therapy medical

"delayed incision healing (such as breast cancer surgery) could postpone adjuvant therapy"

Adjuvant therapy is an extra medical treatment given after the main treatment—often surgery—to reduce the chance that a disease will come back, such as additional drugs, radiation, or immune-based treatments. For investors it matters because successful adjuvant treatments can expand the market for a drug, influence regulatory approval and reimbursement, and change revenue forecasts much like a protective follow-up step that prevents problems from reappearing.

hydrocolloid dressings medical

"Hydrocolloid dressings are recommended to aid in creating a vacuum seal"

Hydrocolloid dressings are adhesive wound coverings that turn into a soft gel when they contact fluid, creating a moist, protected environment that helps skin heal and reduces the need for frequent changes. Think of them as a sticky bandage that seals and cushions a wound while absorbing moisture and blocking germs. Investors watch them because they are a common, regulated medical product with steady demand, reimbursement implications, and margins that affect manufacturers’ sales and regulatory risk.

AI-generated analysis. Not financial advice.

New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care

Solventum™  Prevena™ Therapy is the only closed incision negative pressure therapy system with fully integrated linear and area dressings solely indicated for closed incisions that utilize ROCF technology

ST. PAUL, Minn., Dec. 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the consensus recommendations of an international, multidisciplinary panel of surgeons and wound care experts on the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings.¹ The updated recommendations, appearing in the International Wound Journal,² underscore the evolution of ciNPT from a long-established adjunct to incision management into a therapy that can be applied in a variety of surgical procedures that directly align with healthcare professionals' global priorities around patient safety. Solventum Prevena™ Therapy is the only ciNPT that uses ROCF dressings, a proprietary design element unique to Prevena.

ciNPT is used to manage and protect surgical incisions, particularly in patients at high risk of complications. It works by applying continuous negative pressure to the incision site, helping to remove fluid and reduce tension on the incision. A peer-reviewed meta-analysis of 84 studies across various surgical specialties demonstrated the therapy provided by ciNPT can help reduce the risk of surgical site complications (SSC), dehiscence, skin necrosis and readmissions compared to the standard of care dressing.³ Plastic and reconstructive surgeries of the breast and abdomen, orthopedic surgeries (total joint replacements), traumatic fractures, cardiothoracic surgeries and vascular procedures have widely benefited from the use of ciNPT to optimize the healing environment.

"ciNPT is a prime example of an established standard of care that continues to evolve with evidence and technology," said Dr. H. John Cooper, study author and associate professor of orthopedic surgery, Columbia University Irving Medical Center, New York-Presbyterian Hospital.⁴ "This consensus underscores the benefits of the use of ciNPT across surgical sub-specialties in managing high-risk patients."

Advances in shapes and sizes of foam dressing design — including expanded area coverage options offered by Prevena Restor™ Dressings — have broadened ciNPT's utility across a wider range of incision types and anatomical challenges. The consensus recommendations provide new guidance for dressing selection, highlight specific risk factors warranting ciNPT use and outline technical considerations to improve application consistency and patient outcomes.

A total of 12 consensus statements emerged from the panel, based on a thorough review of recent publications, case studies and clinical experiences involving ciNPT with ROCF. By clarifying where this therapy may provide the most value, these recent recommendations will help drive standardization of practice for at-risk surgical patients worldwide. Key highlights include:

• Risk-based indications: ciNPT dressings with ROCF are recommended for patients with ≥ 2 risk factors, incisions at high risk of seroma formation, revision surgeries, traumatic wounds and scenarios where delayed incision healing (such as breast cancer surgery) could postpone adjuvant therapy. Additionally, ciNPT may be offered for elective use for incisions in which scarring is a concern.
  
  
• Linear vs. area coverage: Area ciNPT dressings are preferred for complex incision geometries (e.g., intersecting or branching incisions), flap closures and sites prone to edema or lymphedema. Linear dressings remain effective for standard, high-tension incisions.
  
  
• Integration into protocols: ciNPT should proactively be included in SSC prevention bundles for high-risk patients and used alongside validated incision risk scoring systems.
  
  
• Application guidance: Hydrocolloid dressings are recommended to aid in creating a vacuum seal in difficult locations.

For more details, the full open-access article is available here. The panel emphasized that these recommendations not only address immediate clinical needs but also lay the foundation for future guideline development. Importantly, they resonate with findings from a recent global healthcare innovation survey that identified patient safety as one of the top three priorities for medical professionals worldwide.

"The international consensus highlights a shift in ciNPT from a selective adjunct to an essential element of evidence-based, post-operative care," said Ryan Egeland, MD, chief medical officer, Solventum. "By listening to our customers, we see how surgical teams are applying our products in new ways to address clinical challenges. Prevena™ Therapy exemplifies how established interventions can continue to evolve in alignment with advancing clinical priorities to improve safety and outcomes."

For more information including safety and clinical considerations, visit Prevena.com.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com. 

Forward-Looking Statements
This news release contains forward-looking information about Solventum's business prospects and therapies that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would" and other words and terms of similar meaning in connection with any discussion of future business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions and other events beyond Solventum's control; (2) operational execution risks; (3) damage to our reputation or our brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) Solventum's business dealings involving third-party partners in various markets; (6) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (7) reduction in customers' research budgets or government funding; (8) the timing and market acceptance of Solventum's new product and service offerings; (9) ongoing working relationships with certain key healthcare professionals; (10) changes in reimbursement practices of governments or private payers or other cost containment measures; (11) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions and disruptive factors; (12) risks related to the highly regulated environment in which Solventum operates; and (13) Solventum's failure to obtain, maintain, protect or effectively enforce its intellectual property rights.

Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

^{_________________________________
1} Solventum Prevena™ Therapy is the only ciNPT dressing that uses ROCF.
² Singh D, Alton T, Alvand A, et al. Linear and Area Coverage with Closed Incision Negative Pressure Therapy Management: International Multidisciplinary Consensus Recommendations. Int Wound J. 2025;22:e7067.
³ Cooper HJ, Singh DP, Gabriel A, Mantyh C, Silverman R, Griffin L. Closed Incision Negative Pressure Therapy Versus Standard of Care Over Closed Surgical Incisions in the Reduction of Surgical Site Complications: A Systematic Review and Meta-Analysis of Comparative Studies. Plastic and Reconstructive Surgery – Global Open. 2023 Mar 16;11(3):e4722.
⁴ Authors Singh, Alton, Alvand, Barbosa, Chatterjee, Djohan, Gomez, Pieri, Sumpio, Willy, Zelle and Cooper had consulting agreements with Solventum Corporation at the time of the expert panel meeting.

View original content to download multimedia:https://www.prnewswire.com/news-releases/global-expert-panel-publishes-new-recommendations-on-advanced-use-of-closed-incision-negative-pressure-therapy-302644897.html

SOURCE Solventum

FAQ

What did Solventum announce about ciNPT with ROCF on Dec 17, 2025 (SOLV)?

An international panel published 12 consensus recommendations on ciNPT with ROCF, covering indications, dressing selection and application tips.

How many studies were included in the meta-analysis cited by Solventum (SOLV)?

The announcement cites a peer-reviewed meta-analysis of 84 studies across multiple surgical specialties.

When is ciNPT with ROCF recommended according to the new Solventum guidance (SOLV)?

The guidance recommends ciNPT with ROCF for patients with ≥2 risk factors, high seroma risk incisions, revisions, traumatic wounds, and delayed-healing scenarios.

What makes Prevena Therapy distinct in the Solventum announcement (SOLV)?

Prevena is described as the only closed incision negative pressure therapy system that uses ROCF dressings and offers integrated linear and area dressings.

How do the consensus recommendations affect dressing choice for complex incisions (SOLV)?

They prefer area ciNPT dressings for intersecting or branching incisions, flap closures, and sites prone to edema or lymphedema.

Where can clinicians find the full Solventum consensus recommendations (SOLV)?

The recommendations are published in the International Wound Journal and available as an open-access article.